Hormone replacement therapy after treatment of endometrial cancer

Gynecologic and Obstetric Investigation

Volumn 65, Issue 1, 2008, Pages 35-38

  Tangjitgamol, Siriwan ^a   Manusirivithaya, Sumonmal ^a   Hanprasertpong, Jitti ^b   Kavanagh, John J ^c  

^a NAVAMINDRADHIRAJ UNIVERSITY   (Thailand)

^b PRINCE OF SONGKLA UNIVERSITY   (Thailand)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

After cancer treatment; Endometrial cancer; Estrogen or hormone replacement therapy

Indexed keywords

CONJUGATED ESTROGEN; MEDROXYPROGESTERONE; MEDROXYPROGESTERONE ACETATE;

CANCER RESEARCH; DRUG SAFETY; ENDOMETRIUM CANCER; ESTROGEN THERAPY; FEMALE; GYNECOLOGIC CANCER; HORMONE SUBSTITUTION; HUMAN; MORTALITY; PATIENT SELECTION; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENCE RISK; RETROSPECTIVE STUDY; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR;

ENDOMETRIAL NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; PROGESTERONE;

EID: 38349090491     PISSN: 03787346     EISSN: None     Source Type: Journal    
DOI: 10.1159/000106776     Document Type: Review

References (9)

1. Creasman WT, Henderson D, Hinshaw W, Clarke-Pearson DL: Estrogen replacement therapy in the patient treated for endometrial cancer. Obstet Gynecol 1986;67:326-330.
2. Lee RB, Burke TW, Park RC: Estrogen replacement therapy following treatment for stage I endometrial carcinoma. Gynecol Oncol 1990;36:189-191.
3. Bryant GW: Administration of estrogens to patients with a previous diagnosis of endometrial adenocarcinoma. South Med J 1990;83:725-726.
4. Gitsch G, Hanzal E, Jensen D, Hacker NF: Endometrial cancer in premenopausal women 45 years and younger. Obstet Gynecol 1995;85:504-508.
5. Chapman JA, DiSaia PJ, Osann K, Roth PD, Gillotte DL, Berman ML: Estrogen replacement in surgical stage I and II endometrial cancer survivors. Am J Obstet Gynecol 1996;175:1195-1200.
6. Suriano KA, McHale M, McLaren CE, Li KT, Re A, DiSaia PJ: Estrogen replacement therapy in endometrial cancer patients. Obstet Gynecol 2001;97:555-560.
7. Ayhan A, Taskiran C, Simsek S, Sever A: Does immediate hormone replacement therapy affect the oncologic outcome in endometrial cancer survivors? Int J Gynecol Cancer 2006;16:805-808.
8. Barakat RR, Bundy BN, Spirtos NM, Bell J, Mannel RS; Gynecologic Oncology Group Study: Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2006;24:587-592.
9. Writing Group for the Women's Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.